Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

NCT02091245 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Acute Lymphoblastic Leukemia (ALL)
Refractory Acute Lymphoblastic Leukemia (ALL)
Relapsed Acute Myelogenous Leukemia (AML)
Refractory Acute Myelogenous Leukemia (AML)
Relapsed Mixed Lineage Leukemia
Refractory Mixed Lineage Leukemia
Relapsed Biphenotypic Leukemia
Refractory Biphenotypic Leukemia
Chronic Myelogenous Leukemia (CML) in Blast Crisis

Interventions

DRUG: KPT-330

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]